Identification of a serum biomarker signature associated with metastatic prostate cancer

Summary, in English

Purpose: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. Experimental design: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. Results: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. Conclusions and clinical relevance: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.

• Author: Venera Kuci Emruli; Leena Liljedahl; Ulrika Axelsson; Corinna Richter; Lisa Theorin; Anders Bjartell; Hans Lilja; Jenny Donovan; David Neal; Freddie C. Hamdy; Carl A.K. Borrebaeck
• Department/s: LUCC: Lund University Cancer Centre; Department of Immunotechnology; Create Health; Urological cancer, Malmö; EpiHealth: Epidemiology for Health; Clinical Chemistry, Malmö
• Publishing year: 2021-05-01
• Language: English
• Publication/Series: Proteomics - Clinical Applications
• Volume: 15
• Issue: 2-3
• Links: http://dx.doi.org/10.1002/prca.202000025
• Document type: Journal article
• Publisher: John Wiley & Sons Inc.
• Topic: Cancer and Oncology
• Keywords: affinity proteomics; antibody microarrays; biomarkers; cancer; prostate cancer
• Status: Published
• Research group: Urological cancer, Malmö; Clinical Chemistry, Malmö
• ISBN/ISSN/Other: ISSN: 1862-8346